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ciani hlvc contmued 10 purrue suppression of ventricular 
:arrhythmmc ,I’ a therapeutic goal in such patients. In one 
wdi 17). S:‘ii IO 73% of the cardiologists urveyed indicated 
th;: :Lc; ;iml: :ria: ;m;rkiilar arrhyi’hmiar in asympto- 
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matx p,nun\ who had had a recent myocardial infarctmn 
171. In another study (8). 41% and lY7c of the cardiologists 
son Fr”“ris<” Cn,i%min . , m~crv~ewd would empmcally treat asymptomatic venlricu- 
lx premature depolatirattons and nonsustained venmcuk?: 
rachycxdia. respectively. However. the practice of treating 
Anliarrhytbmic treatment cf asymptomatic ventricular ar- a~ympromatx ventrwlar arrhythmtas in patients with pre- 
rhvihmiss. The oroenoztic s;ar;,:.taoce of ventricular DE- viow myocxdial inFarction was senously questioned when _ 
mature depolarizations in pat&s who wrvive acotc my”- Ihc rccuh~ of the Cardiac Arrhythmia Suppression Trial 
cardial infarction is well established t 1.2. Loaic u~~c~t\ (CAST1 we-e nublished in 1989 (91. 
that patient survival would be improved by ehmliatingfhese CAST ih B prospective. randomized, placebo-contro!!ed. 
makers for cardiac mortality. The common practw of double-blind study to test the hypothesis that sopprcs.ion Of 
tnating asymotomatic ventricular arrhythmias with antiar- vcntiicular arrhvthmias educes arrhythmic death in patients 
iuythn& &ents in postmyocardial mfarction patients had 
been based on the presumptive positive correlation between 
arrhythmia suppression and improved survival. However. 
whether &mination of ventricular arrhythmia leads to 
improved survival remains to he defined. For example. in 
1983 Furberg (3) examined six randomized controlled long- 
term (4 to 24 month follow-up) trials of antiarrhythmic 
therapy with phenytoin. tocainide. mexiletine and aprindinr 
in patients with myocardial infarction and concluded that. 
despite modemle to substantial suppression of ventncular 
ewmic aetivitv. there were no statistical ai5erences in total . . 
mortality between control and treatment groups. In the 
IMPACT study (41 there were no statistical diCrences in 
mortality between mexiletine and placebo treatment groups. 
Another study (5) failed to demonstrate a reduction in I year 
mortalily with prophylactic antiarrhythmic treatment of high 
risk survtvors ot myocardial infarction. Although in general 
these studies did not demonstrate a significant effeci. there 
were suggestions that antiarrhytbmic dtug treatment may 
actually have an adverse effect on survival in this patient 
population. Indeed. more recently. Hine et al (61 demon- 
strated with meta-analysis a statistically significant increnre 
in monality in patients who received antiarrhythmic treat- 
ment as compared with control groups. 
The CAST study. Despite a lack of convincing data to 
support a positive outcome with antiarrhythmic treatment in 
patients with history of myocardial infarction. many physi- 
with modcmte left ventricular dysfunction after myocardial 
mfuction. Two tvoe IC antiarrhvthmic dross. encainide and 
flcwaidc. acd a’~henolhmzine herivative~moricinine l th- 
mono). were selected for the active treatment mm. After IO 
months ofrrcaow~t, the patients treated with encainide and 
Aecmmde had a significxdly higher incidence of death from 
arrhythmns and nonfatal cardiac arrest (4.5%) than did 
pattents treated with placebo lI.Z%t. and the treatment arm 
involvmg encainide and Aecainide was therefore discontin- 
ued. The CAST rcsolts have been the subject of much 
discusdon. The adverse ootcomrs associated with emsinide 
and fiecainide understandably have been extrapolated to 
other type IC and even type IA and IB sodium channel- 
blocking agents. More important. the CAST results drasti- 
cally altered much of our treatment approach to asympto- 
.nalw vcntr~cular arrhvthmias. The previous approach of 
“intention to treat” has been large<; replaced by benign 
neglect in the management of ventricular arrhythmias in this 
group of patients. 
The oresent studv. In this respect he findings of Burkart 
et al. CiO) in the &rent issue dr the Ioumal &e intriguing 
and provocative. In a prospective. randomized. open label 
study the incideace rates of total monalily. sudden death 
and life-rhrcatening ventricular aphythmias (ventricular 
tachycardia and ventricular fibrillation) were significantly 
lower m patients with moderate left ventricular dysfunction 
empirically treated with 2W mg of amiodarone d& imme- 
diately after myocardial infarction compared with rates in a 
placebo control group. The patients in the three study atttx 
(indiwdual treatment. amiodarone and control) were well 
matched with regard to left ventricular ejection fractiw and 
severity of ventricular arrhythmias. Patient charactcnstics 
were comparable with those m the CAST study. One major 
ddTereace in the study design is the timing of recruitment of 
patients with respect o the occurrence of myocardial infarc- 
lion. In the CAST study. patients were rectuired 6 days to 2 channels. amicdamne alsoexhibits beta-adrenergic blocking 
years after myocardial infarction to begin the open label effects (23.24). Beta-adrenergic antagonists have been 
titration phase of the study. Moreover, only patients with shown unequivocally to reduce the incidence of sodden 
arrhythmias aoccessfully suppressed by encainide, Recainide death in survivors of myocardinl infaxtion (25). As pointed 
or moricizine were nndomized m the placebo-controlled out by Burkart et al. (IO). as a result of its beta-blocking 
trial. properties. amiodarone may have a favorable effect on 
The relatively long interval between occurrence of myo- survival beyond a direct electrophysiologic mechanism. 
cardial infarction and the double-bhnd placebocontrolled An interesting apparent ditTerence in the patient charac- 
phase in the CAST study may well have contributed to the teristics in the present study is worth mentioning. The 32% 
very low incidence of sudden death l I .2%l and total mortal- incidence rate of anterior myocardial iofarction in the amio- 
ity (3.0%) in the placebo group (II) because most deaths damoe treatment group was lower than the rate (44%) itt the 
among survivors of acute myocardial infarction oxor within contml and individual treatment groups. Anterior myocar- 
the first 6 months 112). The selection of oatients who dial infarction has been demonstrated to have a higher 
responded to antiarrhylhmic drug treatme& may have 
yielded a lower risk group compared with patients with 
ventricular arrhythmias unresponsive to drug treatment 
(13.14). In the present study. patients with acute myocardial 
infarction who met the entry criteria were immediately 
randomized to one of the three I:eatment arros before 
discharge from the hospital. Unlike the CAST study, in this 
study there was no open titration phase to select treatment 
responders. Thus. not unexpectedly, the total mortality rate 
of 13% in the control group is much higher than that in the 
CAST study but more comparable to previously reported 
values (12). 
As indicated by Burke; et al. (IO). amiodarone has an 
antitibtillatory effect. The cellular mechanism of its antiar- 
Wby b amiodarone effective? A plausible and obvious 
explanation for the favorable outcome of amiodarone treat- 
ment is that this agent is effective in preventing sudden death 
rewltingfrom ventriculartachycardiaaod fibrillation. Thisis 
suggested by a significant difference in the incidence of 
lie-threatening arrhythmia events between the control and 
the amiodarone group. In fact, amiadarone is perhaps the 
most effective agent currently available (IS) for treatment of 
sustained ventriculartachycardia nd ventricular fibrillation. 
mortality rate than inferior myuardial infarction even after 
correction for infarct six (26.27). One has to wonder if the 
apparent lower incidence of anterior myccardial infarction 
effected the outcome in the amiodarone treatment group. 
Implirntiotts. Because of the serious side effects of ami- 
c&one (28). its potential benefil in reducing arrhythmic 
at lower doses may rest;11 in unxceptable adverse morbidity 
mortality has to be carefully examined in a much larger 
group of patients. The most worrisome adverse dfect is 
and mortalitv lhat rnw twaate the favorable effect of amio. 
pulmonary fibrosis. which has been reported in I% to 13% of 
patients treated with amiodamne and has a mortality rate of 
10% to23A (15,uI). This rate may be II% to 15% in patients 
treated for > t year. There is also evidence for increased 
frequency of putmonary fibrosis with time of treatment and 
with cumulativedose (28). Burkartetal. (10) did not observe 
any DWI pulmonary toxicity during I year of amiodarone 
treatment. However, because no pulmonary fuction tests 
were perfoormed, the possibility of pulmonary dysfunction 
such es reduced vital capacity and diffusion capacity cannot 
be ruled out. In genetal. lowering the daily dose of amio- 
darone reduces the incidence of major adverse effects. 
However, as discussed previously. long-term treatment even 
rhythmic action is not clear. Amiodarone has unique elec- 
lrophysiologic properties tha: are not shared by other anti- 
arrhythmis agents. It is classified as a type 3 agent because 
it prolongs cardiac action po!ential duration (16). Prolonga- 
tion of action potential is probably due to its blocking e&cl 
on tbe inward rectifying (17) and the delayed rectifying 
potassium channels (18). It also exhibits use-dependent 
block ofihe cardiac sodium channel (19.20). In this respect, 
it can be catezorized as a tvoe I antiarrhvthmic went. It 
preferen!ially khibits cardiac sodium channels in th;inacti- 
vated state. Thus, amiodarone slows conduction in Purkioje 
fibers and mpocardial tissues, especially in rapidly beating 
partially depolarized ischemic tissues. Moreover, it has been 
shown to inhibit adenosine triphosphate (ATP)-scositive 
potassium cha-mel activity (21). which may play a significant 
role in modulating arrhythmogenesis during mywardial 
ischemia (22:. 
In addition to its direct blocking effects on various cardiac 
darone on s&&al the&gh reduction in sudden death and 
life-threatening ventricular arrhythmias. A daily dose of 200 
mg of amiodarotte has been shown to be effective in treating 
life-threatening ventricular arrhythmias. It remains to be 
seen if lower doses would maintain the same beneficial effect 
while reducing the iocidence of adverse events. 
In view of the findings of CAST, the present study by 
Burkart et al. (IO) is intriguing and provocative. The bene- 
ficial results observed in the amiodarone treatment group are 
encouraging and warrant further investigation. This report 
clearly serves as a pilot study for a large scale prospective 
multicenter randomized placebo-conlrolled trial. 

